Observations following discontinuation of long-term denosumab therapy von McClung, M. R., Wagman, R. B., Miller, P. D., Wang, A., Lewiecki, E. M.

Volltext

Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates von Miller, P. D, Pannacciulli, N, Brown, J. P, Czerwinski, E, Nedergaard, B. S, Bolognese, M. A, Malouf, J, Bone, H. G, Reginster, J.-Y, Singer, A, Wang, C, Wagman, R. B, Cummings, S. R

Volltext

PINP as a biological response marker during teriparatide treatment for osteoporosis von Krege, J. H., Lane, N. E., Harris, J. M., Miller, P. D.

Volltext

Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study von Reginster, J-Y, Adami, S, Lakatos, P, Greenwald, M, Stepan, J J, Silverman, S L, Christiansen, C, Rowell, L, Mairon, N, Bonvoisin, B, Drezner, M K, Emkey, R, Felsenberg, D, Cooper, C, Delmas, P D, Miller, P D

Volltext

Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment von MILLER, P. D, SCHWARTZ, E. N, CHEN, P, MISURSKI, D. A, KREGE, J. H

Volltext

The effect of age and bone mineral density on the absolute, excess, and relative risk of fracture in postmenopausal women aged 50-99 : results from the National Osteoporosis Risk A... von SIRIS, E. S, BRENNEMAN, S. K, BARRETT-CONNOR, E, MILLER, P. D, SAJJAN, S, BERGER, M. L, CHEN, Y.-T

Volltext

Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial von McClung, M. R., Lewiecki, E. M., Geller, M. L., Bolognese, M. A., Peacock, M., Weinstein, R. L., Ding, B., Rockabrand, E., Wagman, R. B., Miller, P. D.

Volltext

Magneto-optical characterization of TCO films using standard and enhanced configurations von Syed, M., Reza, S. A., Miller, P. D., Roop, B.

Volltext

Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years von Ferrari, S., Adachi, J. D., Lippuner, K., Zapalowski, C., Miller, P. D., Reginster, J.-Y., Törring, O., Kendler, D. L., Daizadeh, N. S., Wang, A., O’Malley, C. D., Wagman, R. B., Libanati, C., Lewiecki, E. M.

Volltext

A Study of the Direct Spectral Transform for the Defocusing Davey‐Stewartson II Equation the Semiclassical Limit von Assainova, O., Klein, C., McLaughlin, K. D. T.‐R., Miller, P. D.

Volltext

Predictors of falls among postmenopausal women: results from the National Osteoporosis Risk Assessment (NORA) von Barrett-Connor, E, Weiss, T. W, McHorney, C. A, Miller, P. D, Siris, E. S

Volltext

Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women With Postmenopausal Osteoporosis: A Randomized Controlled Trial von Harris, Steven T, Watts, Nelson B, Genant, Harry K, McKeever, Clark D, Hangartner, Thomas, Keller, Michael, Chesnut III, Charles H, Brown, Jacques, Eriksen, Erik F, Hoseyni, Mohammad S, Axelrod, Douglas W, Miller, Paul D, for the Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

Volltext

What is the best balance of benefits and risks among anti-resorptive therapies for postmenopausal osteoporosis von Miller, P. D, Derman, R. J

Volltext

Routine vaccination practice after adult and paediatric allogeneic haematopoietic stem cell transplant: a survey of UK NHS programmes von Miller, P D E, de Silva, T I, Skinner, R, Gilleece, M, Peniket, A, Hamblin, A, Greenfield, D, Anthias, C, Peggs, K, Madrigal, A, Snowden, J A

Volltext

Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data von Cranney, A, Wells, G. A, Yetisir, E, Adami, S, Cooper, C, Delmas, P. D, Miller, P. D, Papapoulos, S, Reginster, J.-Y, Sambrook, P. N, Silverman, S, Siris, E, Adachi, J. D

Volltext

Vertebral Fractures: Clinical Importance and Management von Kendler, D.L., MD, Bauer, D.C., MD, Davison, K.S., PhD, Dian, L., MBBS, Hanley, D.A., MD, Harris, S.T., MD, McClung, M.R., MD, Miller, P.D., MD, Schousboe, J.T., MD, Yuen, C.K., MD, MBA, Lewiecki, E.M., MD

Volltext

Antifracture efficacy of antiresorptive agents are related to changes in bone density von WASNICH, R. D, MILLER, P. D

Volltext

Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker von Pazianas, M., Blumentals, W. A., Miller, P. D.

Volltext

Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study von Miller, P. D., Recker, R. R., Reginster, J.-Y., Riis, B. J., Czerwinski, E., Masanauskaite, D., Kenwright, A., Lorenc, R., Stakkestad, J. A., Lakatos, P.

Volltext

Monthly Oral Ibandronate Therapy in Postmenopausal Osteoporosis: 1‐Year Results From the MOBILE Study von Miller, Paul D, Mcclung, Michael R, Macovei, Liviu, Stakkestad, Jacob A, Luckey, Marjorie, Bonvoisin, Bernard, Reginster, Jean‐Yves, Recker, Robert R, Hughes, Claire, Lewiecki, E Michael, Felsenberg, Dieter, Delmas, Pierre D, Kendler, David L, Bolognese, Michael A, Mairon, Nicole, Cooper, Cyrus

Volltext